dc.creatorUniversidad San Sebastián
dc.creatorUniversidad San Sebastián
dc.creatorUniversidad San Sebastián
dc.creatorUniversidad San Sebastián
dc.creatorJurado-Coronel, Juan C.
dc.creatorÁvila-Rodriguez, Marco
dc.creatorEcheverria, Valentina
dc.creatorHidalgo, Oscar Alejandro
dc.creatorGonzalez, Janneth
dc.creatorAliev, Gjumrakch
dc.creatorBarreto, George E.
dc.date.accessioned2023-05-24T04:49:56Z
dc.date.available2023-05-24T04:49:56Z
dc.date.created2023-05-24T04:49:56Z
dc.date.issued2016-04-01
dc.identifier1871-5273
dc.identifierhttps://repositorio.uss.cl/handle/uss/6256
dc.identifier10.2174/1871527315666160202125519
dc.description.abstractGreen tea is a beverage consumed around the world that is believed to have substantial health benefits such as reducing the risk of cancer, cardiovascular diseases, diabetes and neurodegeneration. This beverage is prepared from the leaves (steamed and dried) of the Camellia sinesis plant and contains strong antioxidant and neuroprotective phenolic compounds from which the most important is (-)-Epigallocatechin-3-gallate. Parkinson’s disease (PD) is the second more common neurodegenerative disorders, after Alzheimer’s disease and is characterized by degeneration of dopaminergic neurons in the pars compact of the substantia nigra of the basal ganglia. It has been shown in pre-clinical and clinical studies that green tea may be able to prevent PD, but its optimal dose or a possible mechanism explaining its health benefit in PD has not been properly established. In this review, we discuss the potential role of green tea’s phenolic compounds and their therapeutic effectin modulating key signaling pathways in the PD brain.
dc.languageeng
dc.relationCNS and Neurological Disorders - Drug Targets
dc.titleImplication of green tea as a possible therapeutic approach for Parkinson disease
dc.typeArtículo


Este ítem pertenece a la siguiente institución